JP2019517813A - Ｃｄ８１に対するヒト化及びキメラモノクローナル抗体 - Google Patents

Ｃｄ８１に対するヒト化及びキメラモノクローナル抗体 Download PDF

Info

Publication number
JP2019517813A
JP2019517813A JP2018566226A JP2018566226A JP2019517813A JP 2019517813 A JP2019517813 A JP 2019517813A JP 2018566226 A JP2018566226 A JP 2018566226A JP 2018566226 A JP2018566226 A JP 2018566226A JP 2019517813 A JP2019517813 A JP 2019517813A
Authority
JP
Japan
Prior art keywords
antibody
human
seq
antibodies
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018566226A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019517813A5 (enExample
Inventor
ショシャナ レヴィー，
ショシャナ レヴィー，
オーレリアン マラベル，
オーレリアン マラベル，
ランジャニ ラジャパクサ，
ランジャニ ラジャパクサ，
フェリペ ベンセス−カタラン，
フェリペ ベンセス−カタラン，
チウン−チ クオ，
チウン−チ クオ，
ジエ リウ，
ジエ リウ，
ロナルド レヴィー，
ロナルド レヴィー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of JP2019517813A publication Critical patent/JP2019517813A/ja
Publication of JP2019517813A5 publication Critical patent/JP2019517813A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2018566226A 2016-06-16 2017-06-14 Ｃｄ８１に対するヒト化及びキメラモノクローナル抗体 Pending JP2019517813A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662351054P 2016-06-16 2016-06-16
US62/351,054 2016-06-16
PCT/US2017/037533 WO2017218691A1 (en) 2016-06-16 2017-06-14 Humanized and chimeric monoclonal antibodies to cd81

Publications (2)

Publication Number Publication Date
JP2019517813A true JP2019517813A (ja) 2019-06-27
JP2019517813A5 JP2019517813A5 (enExample) 2020-07-27

Family

ID=60664252

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018566226A Pending JP2019517813A (ja) 2016-06-16 2017-06-14 Ｃｄ８１に対するヒト化及びキメラモノクローナル抗体

Country Status (9)

Country Link
US (1) US10815306B2 (enExample)
EP (1) EP3471762A4 (enExample)
JP (1) JP2019517813A (enExample)
CN (1) CN109414492A (enExample)
BR (1) BR112018076247A2 (enExample)
CA (1) CA3027942A1 (enExample)
MA (1) MA45404A (enExample)
RU (1) RU2019100102A (enExample)
WO (1) WO2017218691A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021150266A1 (en) * 2020-01-21 2021-07-29 Tavotek Biotherapeutics (Hong Kong) Limited Agents that interfere with il-1beta receptor signalling
WO2024079192A1 (en) 2022-10-12 2024-04-18 Institut National de la Santé et de la Recherche Médicale Cd81 as a biomarker and biotarget in t-cell malignancies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120141486A1 (en) * 2010-12-06 2012-06-07 Dainippon Sumitomo Pharma Co., Ltd. Human monoclonal antibody

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
WO2006037604A1 (en) 2004-10-01 2006-04-13 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Novel antibodies directed to the mammalian eag1 ion channel protein
US8034902B2 (en) * 2005-05-04 2011-10-11 Quark Pharmaceuticals, Inc. Recombinant antibodies against CD55 and CD59 and uses thereof
EP3530736A3 (en) * 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
US7858752B2 (en) * 2006-12-05 2010-12-28 Abbott Laboratories Recombinant antibodies against hepatitis C virus and methods of obtaining and using same
WO2011016238A1 (en) * 2009-08-06 2011-02-10 Immunas Pharma, Inc. Antibodies that specifically bind to a beta oligomers and use thereof
US20140030771A1 (en) 2010-06-09 2014-01-30 Richard C. Yu Compositions and methods for increasing oil production and secretion
EP2650367A4 (en) * 2010-12-06 2015-07-08 Sumitomo Dainippon Pharma Co Ltd HUMAN MONOCLONAL ANTIBODY
US9725517B2 (en) * 2012-10-26 2017-08-08 Institute Of Basic Medical Sciences, Chinese Academy Of Medical Sciences Humanized monoclonal antibodies against the extracellular domain of human death receptor 5

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120141486A1 (en) * 2010-12-06 2012-06-07 Dainippon Sumitomo Pharma Co., Ltd. Human monoclonal antibody

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANTIVIRAL RESEARCH VOL. 101, JANUARY 2014, PAGES 37-44 , JPN6021025568, ISSN: 0004699167 *
SCANDINAVIAN JOURNAL OF IMMUNOLOGY (1996), 43(4), 367-373, JPN6021025566, ISSN: 0004699168 *

Also Published As

Publication number Publication date
EP3471762A1 (en) 2019-04-24
EP3471762A4 (en) 2020-03-11
CN109414492A (zh) 2019-03-01
BR112018076247A2 (pt) 2019-03-26
WO2017218691A1 (en) 2017-12-21
MA45404A (fr) 2019-04-24
US10815306B2 (en) 2020-10-27
US20190177425A1 (en) 2019-06-13
RU2019100102A (ru) 2020-07-16
CA3027942A1 (en) 2017-12-21
RU2019100102A3 (enExample) 2020-10-14

Similar Documents

Publication Publication Date Title
JP7412521B2 (ja) Ｃｄ４７に対するヒト化及びキメラモノクローナル抗体
US11718675B2 (en) Disrupting FC receptor engagement on macrophages enhances efficacy of anti-SIRPalpha antibody therapy
US10781256B2 (en) Anti SIRP-α antibodies and bi-specific macrophage enhancing antibodies
JP2025020138A (ja) 免疫細胞活性化のための二重特異性抗体
CN113195544A (zh) 多特异性结合蛋白及其使用方法
JP2020506924A (ja) Ｔ細胞エンゲージ抗体コンストラクトを含む低ｐＨ医薬組成物
US11760810B2 (en) Modified immunoglobulin hinge regions to reduce hemagglutination
US20230235090A1 (en) Bispecific antibody and use thereof
US10815306B2 (en) Humanized and chimeric monoclonal antibodies to CD81
WO2022057061A1 (en) Pd-l1 antibodies, fusion proteins, and uses thereof
JP2024542914A (ja) ヒトｃｘｃｌ１６抗体およびその使用
HK40003752A (en) Humanized and chimeric monoclonal antibodies to cd81
CN121941711A (zh) Nkg2a/cd94靶向抗体及其用途
TW202602924A (zh) 抗ccr8抗體之醫藥配製物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200612

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200612

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210701

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220204